🇺🇸 FDA
Patent

US 8058271

Selective inhibitors of rock protein kinase and uses thereof

granted A61PA61P1/04A61P11/06

Quick answer

US patent 8058271 (Selective inhibitors of rock protein kinase and uses thereof) held by Vertex Pharmaceuticals Incorporated expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P1/04, A61P11/06, A61P13/12, A61P15/06